UNSPSC 51171953: Pibutidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C19H24N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4XRL9PL02Y, chemically known as 3-cyclobutene-1,2-dione, 3-amino-4-((4-((4-(1-piperidinylmethyl)-2-pyridinyl)oxy)-2-butenyl)amino)-, (z)- but generally known as pibutidine, which bears US NIH Compound Identifier 5282450. European Medicines Agency schedules Pibutidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09805MIG.

UNSPSC 51171953 Pibutidine (Commodity) covers pharmaceutical supply and testing services in state and local criminal justice and health programs, though recent solicitation activity under this code shows a mismatch with its nominal scope. The three recent opportunities posted span drug testing services for offender supervision, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing — none of which align specifically with pibutidine as a pharmaceutical ingredient. Issuing bodies include county criminal justice departments, state health and human services commissions, and multistate cooperative purchasing alliances administering programs for participating states and localities. The scope of work under recent postings encompasses specimen collection and lab-confirmed drug screening (immunoassay with LC/MS/MS or GC/MS confirmation), pharmacy benefit program design and direct contracting, and bulk pharmaceutical distribution through authorized wholesalers.

Activity concentrates in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services with proposals due July 23, 2026, covering approximately 25,031 annual tests at an estimated contract value of $600,000 over two years plus optional renewals. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026 (response deadline April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs without formal evaluation criteria or award amounts at this preliminary phase. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities including Oregon, with no disclosed award values but performance penalties of $200 to $1,500 per violation and a 3 percent administrative fee on contract purchases. The code shows limited concrete recent activity directly tied to pibutidine procurement.